Systemic and Local Administration of a Dual-siRNA Complex Efficiently Inhibits Tumor Growth and Bone Invasion in Oral Squamous Cell Carcinoma

Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis. RNA-based gene therapies have been developed as an emerging option for cancer treatment, but it has not been widely explored in OSCC. In this...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmaceutics Vol. 21; no. 2; pp. 661 - 676
Main Authors Ma, Pingchuan, He, Mingxia, Lian, Haosen, Li, Jingmei, Gao, Yan, Wu, Jieping, Men, Ke, Men, Yi, Li, Chunjie
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 05.02.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis. RNA-based gene therapies have been developed as an emerging option for cancer treatment, but it has not been widely explored in OSCC. In this work, we developed an efficient siRNA cationic micelle DOTAP-mPEG–PCL (DMP) by self-assembling the cationic lipid DOTAP and monomethoxy poly­(ethylene glycol)-poly­(ε-caprolactone) (mPEG–PCL) polymer. We tested the characteristics and transformation efficiency of this micelle and combined DMP with siRNA targeting STAT3 and TGF-β to evaluate the antitumor effect and bone invasion interfering in vitro and in vivo. The average size of the DMP was 28.27 ± 1.62 nm with an average zeta potential of 54.60 ± 0.29 mV. The DMP/siRNA complex showed high delivery efficiency, with rates of 97.47 ± 0.42% for HSC-3. In vitro, the DMP/siSTAT3 complex exhibited an obvious cell growth inhibition effect detected by MTT assay (an average cell viability of 25.1%) and clonogenic assay (an average inhibition rate of 51.9%). Besides, the supernatant from HSC-3 transfected by DMP/siTGF-β complexes was found to interfere with osteoclast differentiation in vitro. Irrespective of local or systemic administration, DMP/siSTAT3+siTGF-β showed antitumor effects and bone invasion inhibition in the OSCC mice mandibular invasion model according to tumor volume assays and Micro-CT scanning. The complex constructed by DMP cationic micelles and siSTAT3+siTGF-β represents a potential RNA-based gene therapy delivery system for OSCC.
AbstractList Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis. RNA-based gene therapies have been developed as an emerging option for cancer treatment, but it has not been widely explored in OSCC. In this work, we developed an efficient siRNA cationic micelle DOTAP-mPEG–PCL (DMP) by self-assembling the cationic lipid DOTAP and monomethoxy poly­(ethylene glycol)-poly­(ε-caprolactone) (mPEG–PCL) polymer. We tested the characteristics and transformation efficiency of this micelle and combined DMP with siRNA targeting STAT3 and TGF-β to evaluate the antitumor effect and bone invasion interfering in vitro and in vivo. The average size of the DMP was 28.27 ± 1.62 nm with an average zeta potential of 54.60 ± 0.29 mV. The DMP/siRNA complex showed high delivery efficiency, with rates of 97.47 ± 0.42% for HSC-3. In vitro, the DMP/siSTAT3 complex exhibited an obvious cell growth inhibition effect detected by MTT assay (an average cell viability of 25.1%) and clonogenic assay (an average inhibition rate of 51.9%). Besides, the supernatant from HSC-3 transfected by DMP/siTGF-β complexes was found to interfere with osteoclast differentiation in vitro. Irrespective of local or systemic administration, DMP/siSTAT3+siTGF-β showed antitumor effects and bone invasion inhibition in the OSCC mice mandibular invasion model according to tumor volume assays and Micro-CT scanning. The complex constructed by DMP cationic micelles and siSTAT3+siTGF-β represents a potential RNA-based gene therapy delivery system for OSCC.
Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis. RNA-based gene therapies have been developed as an emerging option for cancer treatment, but it has not been widely explored in OSCC. In this work, we developed an efficient siRNA cationic micelle DOTAP-mPEG-PCL (DMP) by self-assembling the cationic lipid DOTAP and monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) (mPEG-PCL) polymer. We tested the characteristics and transformation efficiency of this micelle and combined DMP with siRNA targeting STAT3 and TGF-β to evaluate the antitumor effect and bone invasion interfering in vitro and in vivo. The average size of the DMP was 28.27 ± 1.62 nm with an average zeta potential of 54.60 ± 0.29 mV. The DMP/siRNA complex showed high delivery efficiency, with rates of 97.47 ± 0.42% for HSC-3. In vitro, the DMP/siSTAT3 complex exhibited an obvious cell growth inhibition effect detected by MTT assay (an average cell viability of 25.1%) and clonogenic assay (an average inhibition rate of 51.9%). Besides, the supernatant from HSC-3 transfected by DMP/siTGF-β complexes was found to interfere with osteoclast differentiation in vitro. Irrespective of local or systemic administration, DMP/siSTAT3+siTGF-β showed antitumor effects and bone invasion inhibition in the OSCC mice mandibular invasion model according to tumor volume assays and Micro-CT scanning. The complex constructed by DMP cationic micelles and siSTAT3+siTGF-β represents a potential RNA-based gene therapy delivery system for OSCC.
Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis. RNA-based gene therapies have been developed as an emerging option for cancer treatment, but it has not been widely explored in OSCC. In this work, we developed an efficient siRNA cationic micelle DOTAP-mPEG-PCL (DMP) by self-assembling the cationic lipid DOTAP and monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) (mPEG-PCL) polymer. We tested the characteristics and transformation efficiency of this micelle and combined DMP with siRNA targeting STAT3 and TGF-β to evaluate the antitumor effect and bone invasion interfering and . The average size of the DMP was 28.27 ± 1.62 nm with an average zeta potential of 54.60 ± 0.29 mV. The DMP/siRNA complex showed high delivery efficiency, with rates of 97.47 ± 0.42% for HSC-3. , the DMP/siSTAT3 complex exhibited an obvious cell growth inhibition effect detected by MTT assay (an average cell viability of 25.1%) and clonogenic assay (an average inhibition rate of 51.9%). Besides, the supernatant from HSC-3 transfected by DMP/siTGF-β complexes was found to interfere with osteoclast differentiation . Irrespective of local or systemic administration, DMP/siSTAT3+siTGF-β showed antitumor effects and bone invasion inhibition in the OSCC mice mandibular invasion model according to tumor volume assays and Micro-CT scanning. The complex constructed by DMP cationic micelles and siSTAT3+siTGF-β represents a potential RNA-based gene therapy delivery system for OSCC.
Author Men, Yi
He, Mingxia
Gao, Yan
Wu, Jieping
Ma, Pingchuan
Li, Chunjie
Lian, Haosen
Li, Jingmei
Men, Ke
AuthorAffiliation State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology
West China Hospital of Sichuan University
Joint National Laboratory for Antibody Drug Engineering, School of Medicine
State Key Laboratory of Biotherapy and Cancer Center
AuthorAffiliation_xml – name: West China Hospital of Sichuan University
– name: State Key Laboratory of Biotherapy and Cancer Center
– name: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology
– name: Joint National Laboratory for Antibody Drug Engineering, School of Medicine
Author_xml – sequence: 1
  givenname: Pingchuan
  orcidid: 0000-0003-2298-7224
  surname: Ma
  fullname: Ma, Pingchuan
  organization: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology
– sequence: 2
  givenname: Mingxia
  surname: He
  fullname: He, Mingxia
  organization: Joint National Laboratory for Antibody Drug Engineering, School of Medicine
– sequence: 3
  givenname: Haosen
  surname: Lian
  fullname: Lian, Haosen
  organization: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology
– sequence: 4
  givenname: Jingmei
  surname: Li
  fullname: Li, Jingmei
  organization: West China Hospital of Sichuan University
– sequence: 5
  givenname: Yan
  orcidid: 0000-0002-1933-724X
  surname: Gao
  fullname: Gao, Yan
  organization: West China Hospital of Sichuan University
– sequence: 6
  givenname: Jieping
  surname: Wu
  fullname: Wu, Jieping
  organization: West China Hospital of Sichuan University
– sequence: 7
  givenname: Ke
  orcidid: 0000-0002-0587-9961
  surname: Men
  fullname: Men, Ke
  organization: West China Hospital of Sichuan University
– sequence: 8
  givenname: Yi
  surname: Men
  fullname: Men, Yi
  email: yurimen@163.com
  organization: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology
– sequence: 9
  givenname: Chunjie
  surname: Li
  fullname: Li, Chunjie
  email: lichunjie07@qq.com
  organization: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38175819$$D View this record in MEDLINE/PubMed
BookMark eNqNkctu2zAQRYkiRfNof6Fgd93I4UMPaumqzgMwGqBJ18KYImEGIumQVBp_RP45dOwE6K6rITB3ztzhPUVHzjuF0DdKZpQweg4yzqwfN2sIFqSa0oxLQgRhH9AJrUpeCN6yo_e3KI_RaYz3hLCyYvwTOuaCNpWg7Ql6vt3GpKyRGNyAl17CiOeDNc7EFCAZ77DXGPDPCcYimt-_5rjzdjOqJ7zQ2kijXBq3-NqtzcqkiO8m6wO-DP5vWr8if2Truf0IcccyDt-EvOL2YQLrp4g7NY64gyCN8xY-o48axqi-HOoZ-nOxuOuuiuXN5XU3XxbAa54KWreCallRgEYKaAbFgNSiaVldgWxXVHG5kko0uqlJowYigNaaEQIV0SVn_Ax933M3wT9MKqbemiizFXAqu-pZy1hZNiUXWdrupTL4GIPS_SYYC2HbU9Lv0uhzGv0_afSHNPLs18OaaWXV8D759v1ZUO0FO8a9n4LLV_8H-AWPH6F7
CitedBy_id crossref_primary_10_3390_ijms25105083
Cites_doi 10.1111/j.1601-0825.2010.01781.x
10.1186/s12951-021-01088-9
10.1016/j.yexcr.2008.06.006
10.1002/smll.201802565
10.1166/jbn.2018.2593
10.2147/IJN.S357702
10.1002/advs.201900667
10.1038/bjc.2017.239
10.1021/acs.molpharmaceut.1c00461
10.3109/15412555.2013.813928
10.1016/j.oraloncology.2017.02.016
10.1016/j.pdpdt.2021.102581
10.1016/j.tranon.2021.101236
10.1016/j.canlet.2014.12.052
10.1016/j.oraloncology.2012.08.004
10.1111/jop.13268
10.1080/1061186X.2018.1502775
10.1158/1535-7163.MCT-11-0648
10.1166/jbn.2020.2961
10.1038/gt.2017.6
10.1016/j.biomaterials.2018.09.017
10.1007/s10555-011-9335-7
10.1002/jgm.3097
10.1111/cbdd.12993
10.1039/C7RA13656K
10.1097/CJI.0000000000000166
10.1186/1471-2407-13-605
10.1172/JCI125336
10.2174/0929867328666201207202012
10.1016/j.bbrc.2015.02.013
10.1038/nrclinonc.2018.8
10.3109/1061186X.2015.1070856
10.1080/14712598.2020.1738377
10.1016/j.bbrc.2020.11.073
10.1016/j.jconrel.2012.01.045
10.1021/acs.nanolett.7b01571
10.7150/thno.45164
10.1038/s41556-021-00641-w
10.3390/cancers12071889
10.2147/IJN.S277845
10.3892/mmr.2017.7625
10.1126/sciadv.aay3324
10.3322/caac.21492
10.1039/c2nr30079f
10.1016/j.semcancer.2018.01.008
10.4317/medoral.18772
10.1016/j.jconrel.2012.05.005
10.1016/j.ebiom.2019.08.013
10.1016/j.bone.2008.03.026
10.1038/s41467-022-31475-1
10.1002/ijc.33579
ContentType Journal Article
Copyright 2024 American Chemical Society
Copyright_xml – notice: 2024 American Chemical Society
DBID NPM
AAYXX
CITATION
7X8
DOI 10.1021/acs.molpharmaceut.3c00802
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1543-8392
EndPage 676
ExternalDocumentID 10_1021_acs_molpharmaceut_3c00802
38175819
a103371425
Genre Journal Article
GroupedDBID ---
-~X
123
4.4
53G
55A
5VS
7~N
AABXI
ABFRP
ABJNI
ABMVS
ABQRX
ABUCX
ACGFS
ACS
ADHLV
AEESW
AENEX
AFEFF
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
CS3
DU5
EBS
ED~
F5P
GGK
GNL
H~9
IH9
JG~
P2P
RNS
ROL
UI2
VF5
VG9
W1F
BAANH
CUPRZ
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-a363t-16981fc51aa7c8a7de2a06879265ac9b1e3cbce87f7607ed08a16f200a50f4323
IEDL.DBID ACS
ISSN 1543-8384
IngestDate Fri Aug 16 20:37:15 EDT 2024
Fri Aug 23 01:51:39 EDT 2024
Sat Nov 02 12:11:04 EDT 2024
Tue Feb 06 03:15:53 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords siRNA delivery
gene therapy
oral squamous cell carcinoma
bone invasion
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a363t-16981fc51aa7c8a7de2a06879265ac9b1e3cbce87f7607ed08a16f200a50f4323
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-0587-9961
0000-0003-2298-7224
0000-0002-1933-724X
PMID 38175819
PQID 2922447438
PQPubID 23479
PageCount 16
ParticipantIDs proquest_miscellaneous_2922447438
crossref_primary_10_1021_acs_molpharmaceut_3c00802
pubmed_primary_38175819
acs_journals_10_1021_acs_molpharmaceut_3c00802
PublicationCentury 2000
PublicationDate 2024-02-05
PublicationDateYYYYMMDD 2024-02-05
PublicationDate_xml – month: 02
  year: 2024
  text: 2024-02-05
  day: 05
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular pharmaceutics
PublicationTitleAlternate Mol. Pharmaceutics
PublicationYear 2024
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref9/cit9
ref45/cit45
ref3/cit3
ref27/cit27
ref16/cit16
ref23/cit23
ref8/cit8
ref31/cit31
ref2/cit2
ref34/cit34
ref37/cit37
ref20/cit20
ref48/cit48
ref17/cit17
ref10/cit10
ref35/cit35
ref19/cit19
ref21/cit21
ref42/cit42
ref46/cit46
ref49/cit49
ref13/cit13
ref24/cit24
ref38/cit38
ref50/cit50
ref6/cit6
ref36/cit36
ref18/cit18
ref11/cit11
ref25/cit25
ref29/cit29
ref32/cit32
ref39/cit39
ref14/cit14
ref5/cit5
ref51/cit51
ref43/cit43
ref28/cit28
ref40/cit40
ref26/cit26
ref12/cit12
ref15/cit15
ref41/cit41
ref22/cit22
ref33/cit33
ref4/cit4
ref30/cit30
ref47/cit47
ref1/cit1
ref44/cit44
ref7/cit7
References_xml – ident: ref8/cit8
  doi: 10.1111/j.1601-0825.2010.01781.x
– ident: ref12/cit12
  doi: 10.1186/s12951-021-01088-9
– ident: ref18/cit18
  doi: 10.1016/j.yexcr.2008.06.006
– ident: ref42/cit42
  doi: 10.1002/smll.201802565
– ident: ref31/cit31
  doi: 10.1166/jbn.2018.2593
– ident: ref32/cit32
  doi: 10.2147/IJN.S357702
– ident: ref2/cit2
  doi: 10.1002/advs.201900667
– ident: ref6/cit6
  doi: 10.1038/bjc.2017.239
– ident: ref33/cit33
  doi: 10.1021/acs.molpharmaceut.1c00461
– ident: ref10/cit10
  doi: 10.3109/15412555.2013.813928
– ident: ref38/cit38
  doi: 10.1016/j.oraloncology.2017.02.016
– ident: ref39/cit39
  doi: 10.1016/j.pdpdt.2021.102581
– ident: ref19/cit19
  doi: 10.1016/j.tranon.2021.101236
– ident: ref40/cit40
  doi: 10.1016/j.canlet.2014.12.052
– ident: ref9/cit9
  doi: 10.1016/j.oraloncology.2012.08.004
– ident: ref23/cit23
  doi: 10.1111/jop.13268
– ident: ref48/cit48
  doi: 10.1080/1061186X.2018.1502775
– ident: ref26/cit26
  doi: 10.1158/1535-7163.MCT-11-0648
– ident: ref24/cit24
  doi: 10.1166/jbn.2020.2961
– ident: ref44/cit44
  doi: 10.1038/gt.2017.6
– ident: ref50/cit50
  doi: 10.1016/j.biomaterials.2018.09.017
– ident: ref7/cit7
  doi: 10.1007/s10555-011-9335-7
– ident: ref36/cit36
  doi: 10.1002/jgm.3097
– ident: ref25/cit25
  doi: 10.1111/cbdd.12993
– ident: ref37/cit37
  doi: 10.1039/C7RA13656K
– ident: ref20/cit20
  doi: 10.1097/CJI.0000000000000166
– ident: ref14/cit14
  doi: 10.1186/1471-2407-13-605
– ident: ref11/cit11
  doi: 10.1172/JCI125336
– ident: ref28/cit28
  doi: 10.2174/0929867328666201207202012
– ident: ref17/cit17
  doi: 10.1016/j.bbrc.2015.02.013
– ident: ref27/cit27
  doi: 10.1038/nrclinonc.2018.8
– ident: ref47/cit47
  doi: 10.3109/1061186X.2015.1070856
– ident: ref30/cit30
  doi: 10.1080/14712598.2020.1738377
– ident: ref21/cit21
  doi: 10.1016/j.bbrc.2020.11.073
– ident: ref46/cit46
  doi: 10.1016/j.jconrel.2012.01.045
– ident: ref43/cit43
  doi: 10.1021/acs.nanolett.7b01571
– ident: ref41/cit41
  doi: 10.7150/thno.45164
– ident: ref15/cit15
  doi: 10.1038/s41556-021-00641-w
– ident: ref22/cit22
  doi: 10.3390/cancers12071889
– ident: ref29/cit29
  doi: 10.2147/IJN.S277845
– ident: ref35/cit35
  doi: 10.3892/mmr.2017.7625
– ident: ref45/cit45
  doi: 10.1126/sciadv.aay3324
– ident: ref1/cit1
  doi: 10.3322/caac.21492
– ident: ref34/cit34
  doi: 10.1039/c2nr30079f
– ident: ref3/cit3
  doi: 10.1016/j.semcancer.2018.01.008
– ident: ref5/cit5
  doi: 10.4317/medoral.18772
– ident: ref51/cit51
  doi: 10.1016/j.jconrel.2012.05.005
– ident: ref4/cit4
  doi: 10.1016/j.ebiom.2019.08.013
– ident: ref13/cit13
  doi: 10.1016/j.bone.2008.03.026
– ident: ref16/cit16
  doi: 10.1038/s41467-022-31475-1
– ident: ref49/cit49
  doi: 10.1002/ijc.33579
SSID ssj0024523
Score 2.4586606
Snippet Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis....
SourceID proquest
crossref
pubmed
acs
SourceType Aggregation Database
Index Database
Publisher
StartPage 661
Title Systemic and Local Administration of a Dual-siRNA Complex Efficiently Inhibits Tumor Growth and Bone Invasion in Oral Squamous Cell Carcinoma
URI http://dx.doi.org/10.1021/acs.molpharmaceut.3c00802
https://www.ncbi.nlm.nih.gov/pubmed/38175819
https://search.proquest.com/docview/2922447438
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSIgL78fy0lRCPTVLYiexcyxLS0FQKrqVeovGjqNG7CawSYDlP_CfGSdZVgtC0GseYyeeyXyZ8XzD2DPNdWJyHXha-8oLTc69BBUSkJOGC5GRRbmM7ruj-PA0fHMWna3ruH_P4PPgOZp6PK9c4ekQ4h0L01WIXmZXuCQjcXhocrIm2Iu6nm4EDYSnhAqvsu1_inKuydSbrukveLPzOwc32HRVvdNvN_k4bhs9Nt__JHO8yCPdZNcHHAp7veLcYpdseZvtHPfXLndhuq7LqndhB47XFNfLO-xHT3ReGMAyg7fOH8ImDS9UOSC8bHHm1cWHoz1wH56Z_Qb7HWcFubrZEl6X54Uumhqm7bxawKtF9bU570S-qEpLp7-gC-ZBUcL7BQ1x8rlFF6qAiZ3NYOLaIJXVHO-y04P96eTQGxo7eChi0XhBnKggN1GAKI1CmVmOfqxkwuMITaIDK4w2Vslcxr60ma8wiHOyZ4z8PBRc3GNbJc3jAQOMIhtL-ivMEEOreWKkFhqtVBmXNMKIkV7W6WCYddrl3HmQuoMbS5AOSzBifKUE6aee8ON_btpeqUtK5ulyLlhaeh8pTwgjhQTT1Ijd7_Xol1hHjhgRInt40Tk-Ytc4KXq3eTx6zLaaRWufEDZq9NPOFn4CGB0QVw
link.rule.ids 315,783,787,2772,27088,27936,27937,57070,57120
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSMCF92N5uhLqqVkSO46dY1latrBdKrqVKvUQjR1HjcgmsEmA5T_wn7GdtKtFQjyuTjKexDOZzx7PZ4ReSCJjlcnAk9IXXqgy4sUgwAA5rgilqfEom9E9mEbj4_DtCTvpd1XaWhijRG0k1S6Jv2IXCF7atnll60_7ld4hVa5Q9DK6wrgxXAuLRkcrnj3mjnYzCIF6gorwKtr8oygboVS9HqF-Aztd-Nm7iU4vFHe7Tj4O20YO1fdfOB3_781uoRs9KsU7nRndRpd0eQdtHXb3LrfxbFWlVW_jLXy4Irxe3kU_OtrzXGEoUzyx0RGvk_LiKsOAX7dQeHX-YbqD7W-o0N_wrmOwMIGvWOL98iyXeVPjWTuvFvjNovranDmRr6pSm8tfwC7t4bzE7xemi6PPLdiFCzzSRYFH9lCksprDPXS8tzsbjb3-mAcPaEQbL4hiEWSKBQBcCeCpJuBHgsckYqBiGWiqpNKCZzzyuU59AUGUGe8G5mchJfQ-2iiNHg8RBsZ0xM0cMQUItSSx4pJK0FykhJseBsiOQNK7aZ24DDwJEtu4NgRJPwQDRM5tIfnU0X_8zUOb51aTGGe1GRgotfkeCYkNYgoNaBMD9KAzpwuxliqRGXz26F91fI6ujWcHk2SyP333GF0nxvbdtnL2BG00i1Y_Naipkc-ce_wEfB0Ytw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELagSBUv3MeWy5VQn5ptYsex87hsu7RQlhXdSn2Lxo6jRuwm7SYBlv_Af8Z20q4WCXG85hg78Uzmy4znG4ReSyJjlcnAk9IXXqgy4sUgwAA5rgilqbEom9H9MI4OT8N3Z-ysC7jZWhgzicpIqlwS31r1RZp1DAPBnj0-L20Nahft7VPlikVvoluMB8S2bhgMT1Zce8y1dzMogXqCinATbf9RlPVSqlr3Ur-Bns4Fje6i5HrybufJ535Ty776_guv4_8_3T10p0OneNCq0310QxcP0M6kvXa5i6eraq1qF-_gyYr4evkQ_Wjpz3OFoUjxsfWSeJ2cF5cZBrzfwMyr8k_jAbafo5n-hg8ck4VxgLMlPirOc5nXFZ4283KB3y7Kr_W5E_mmLLQ5_QVsiA_nBf64MEOcXDZgAxh4qGczPLTNkYpyDo_Q6ehgOjz0unYPHtCI1l4QxSLIFAsAuBLAU03AjwSPScRAxTLQVEmlBc945HOd-gKCKDNWDszPQkroY7RRmHk8RRgY0xE3_4opQKgliRWXVILmIiXcjNBDdhWSzlyrxGXiSZDYg2tLkHRL0EPkSh-Si5YG5G9u2r7SnMQYrc3EQKHN-0hIbJBTaMCb6KEnrUpdi7WUiczgtK1_neMrtDnZHyXHR-P3z9BtYtTf7S5nz9FGvWj0CwOeavnSWchPN94bMQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systemic+and+Local+Administration+of+a+Dual-siRNA+Complex+Efficiently+Inhibits+Tumor+Growth+and+Bone+Invasion+in+Oral+Squamous+Cell+Carcinoma&rft.jtitle=Molecular+pharmaceutics&rft.au=Ma%2C+Pingchuan&rft.au=He%2C+Mingxia&rft.au=Lian%2C+Haosen&rft.au=Li%2C+Jingmei&rft.date=2024-02-05&rft.issn=1543-8384&rft.eissn=1543-8392&rft.volume=21&rft.issue=2&rft.spage=661&rft.epage=676&rft_id=info:doi/10.1021%2Facs.molpharmaceut.3c00802&rft.externalDBID=n%2Fa&rft.externalDocID=10_1021_acs_molpharmaceut_3c00802
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon